The G1/S checkpoint is a critical regulatory point in the cell cycle that ensures a cell is prepared to enter S phase and begin DNA replication. This checkpoint monitors for DNA damage, sufficient cell size and adequate nutrient availability, halting progression if conditions are not optimal. By enforcing a pause in the cycle, the G1/S checkpoint allows time for repair of damaged DNA and is essential for maintaining genomic integrity.
G1 phase of the cell cycle occurs immediately after mitosis and before DNA synthesis (S phase). During the G1 (Gap 1) cell phase, the cell grows in size, produces RNA and proteins necessary for DNA replication and prepares for entry into S phase. At the end of G1 cell phase, the G1/S checkpoint acts as a control mechanism. It assesses whether the cell is ready to make a commitment to DNA replication and division or whether it needs to pause and/or abandon the process.
The G1/S checkpoint monitors several key cellular conditions to ensure the success of cell division and safeguard against premature or inappropriate cell cycle progression. At a basic level, the checkpoint assesses cell size, ensuring the cell has grown enough to support two new daughter cells after mitosis. It also evaluates whether the cell has sufficient nutrients and energy reserves available to support DNA synthesis and mitosis.
With these criteria met, the G1/S checkpoint verifies the presence of external cues that provide the signal for progression and assesses DNA integrity – checking for the presence of DNA damage. If no DNA damage is detected and all other signals concur that the cell is healthy, the cell will be allowed to move into S phase. If DNA damage is detected, the cell cycle process will be paused, allowing for repairs to be completed before resuming. If the DNA damage is too severe, apoptosis may be triggered.
DNA damage is the major inhibitor of S phase entry. The G1/S checkpoint process actively monitors the integrity of the cell’s DNA, initiating a checkpoint signaling cascade that pauses cell cycle progression when DNA damage is detected. The process, which shares many components with the G2/M checkpoint later in the cell cycle, is generally broken into four steps: sensing DNA damage, activating checkpoint kinases, cell cycle arrest and finally, resolution and resumption of the cell cycle.
As with the G2/M checkpoint response later in the cell cycle, the DNA damage response begins with activation of the phosphatidylinositol 3-kinase–like kinases (PIKKs), ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related). ATM is primarily activated by double-strand breaks and is recruited to the damaged site via the MRN complex. ATR responds mainly to single stranded DNA (ssDNA) lesions and is recruited with help from the ATRIP protein and RPA-coated ssDNA.
Once again, similar to the G2M/S checkpoint response, ATM and ATR phosphorylate downstream effector kinases CHK1 and CHK2. At the G1/S phase checkpoint, these kinases contribute to stabilizing and activating p53, the central tumor suppressor protein, by preventing its degradation by MDM2. Activated p53 protein acts as a transcription factor that upregulates the expression of p21, a cyclin-dependent kinase inhibitor.
Cyclin-dependent kinase (CDK) activity is a key driver of the transition from G1 to S phase. p21 directly binds and inhibits the Cyclin E/CDK2 complex. When Cyclin E/CDK2 is inhibited, it can no longer phosphorylate the Rb (retinoblastoma) protein. Unphosphorylated (active) Rb continues to bind and inhibit E2F transcription factors, thereby blocking transcription of replication machinery genes.
Once the DNA damage is repaired, ATM and ATR signaling is diminished, p53 levels decline and p21 is degraded. This relieves inhibition of Cyclin E/CDK2, allowing it to phosphorylate Rb. Phosphorylated Rb releases E2F transcription factors, which then activate genes necessary for S-phase entry and DNA synthesis. Passage through the restriction point commits the cell to S phase, regardless of subsequent extracellular conditions, ensuring orderly progression.
This checkpoint pathway acts as a safeguard, ensuring that only genetically stable cells proceed to DNA replication. Disruption in any part of this pathway, particularly loss of p53 function or deregulation of Cyclin/CDK activity can bypass the checkpoint entirely, allowing cells to replicate damaged DNA – a key hallmark of cancer.
Defective regulation of the G1 phase checkpoint has significant consequences for cellular integrity and cancer development. Mutations in several tumor suppressors such as p53, Rb, Cyclin D, CDK4/6 or p21 frequently disrupt this checkpoint in human cancers. When the checkpoint fails to properly detect or respond to DNA damage, cells proceed into S phase with unrepaired lesions, leading to the accumulation of mutations and genomic instability. Over time, this instability leads to tumorigenesis by enabling the activation of oncogenes and loss of tumor suppressors.
Additionally, impaired checkpoint control disrupts normal cell cycle exit mechanisms, allowing for uncontrolled cell proliferation. This unchecked growth is a hallmark of malignant transformation.
Moreover, many cancer therapies, such as radiation and DNA-damaging chemotherapeutics, rely on intact checkpoint responses to induce cell cycle arrest or apoptosis. In cells with defective G1 checkpoint machinery, especially those with p53 mutations, this damage response is compromised, contributing to resistance to therapy and making treatment less effective.
References